Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15653582 | 0.85 | TAAR1 (0.54) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL9328610 | 0.84 | ESR1 (0.44) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL3466433 | 0.83 | ESR1 (0.47) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL1118667 | 0.83 | TAAR1 (0.52) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL1118743 | 0.83 | TAAR1 (0.52) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL326728 | 0.82 | TDP1 (0.46) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL4943215 | 0.82 | LMNA (0.54) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL22304942 | 0.82 | ESR1 (0.65) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL10255978 | 0.82 | GABBR2 (0.53) | TSHRNFKB1EPHX1ROCK2LMNA | |
| SCHEMBL2738972 | 0.82 | HTR2A (0.47) | EPHX1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1180991-B1 | GAMBOGIC ACID DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2010-05-19 | — | — | EP | claimed |
| EP-1180991-A4 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2005-10-12 | — | — | EP | claimed |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2003-04-24 | — | — | US | claimed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000044216-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000044216-A1 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| EP-1180991-B1 | GAMBOGIC ACID DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090259054-A1 | Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration | THE TEXAS A&M UNIVERSITY SYSTEM | 2009-10-15 | — | — | US | disclosed |
| WO-2008148008-A1 | HIGH THROUGHPUT BIOASSAY FOR IDENTIFYING SELECTIVE TRKA RECEPTOR AGONISTS, AND GAMBOGIC AMIDE, A SELECTIVE TRKA AGONIST WITH NEUROPROTECTIVE ACTIVITY | EMORY UNIVERSITY (US) | 2008-12-04 | — | — | WO | disclosed |
| EP-1620564-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1620564-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1180991-A4 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004094647-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-6613762-B2 | Synergystic mixtures comprising prodrugs, 9,10-dihydrogambogic acid and antibodies, cell growth factors or cytokines, used as anticarcinogenic agents | CYTOVIA, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000044216-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CASP5, CASP3, CASP7 | TAAR1 4047/4885HIF1A 493/4885HTR3A 4243/4885 |
| US-20090259054-A1 | Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration | PDE6D, PDE6H, VEGFA | TAAR1 2556/4885HIF1A 79/4885HTR3A 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.